Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium.
新澤西州福特李，2024年12月10日 (GLOBE新聞社) -- Nuvectis Pharma, Inc. (納斯達克: NVCT) ("Nuvectis" 或 "公司"), 一家臨床階段生物製藥公司，專注於開發創新的精準醫療，以治療腫瘤領域中未滿足醫療需求的嚴重疾病，今天宣佈，董事長兼首席執行官Ron Bentsur將在2024年拉登堡虛擬腫瘤創新者與投資者研討會上進行演講。
| Event | 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium |
| Date | 12 December 2024 |
| Time | 10 am EST |
| 事件 | 2024年拉登堡虛擬腫瘤創新者與投資者研討會 |
| 日期 | 2024年12月12日 |
| 時間 | 上午10點 EST |
About Nuvectis Pharma, Inc.
關於Nuvectis製藥公司
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Nuvectis製藥公司是一家生物製藥公司，專注於開發創新的精準藥物，以治療腫瘤學中未滿足醫療需求的嚴重疾病。該公司目前正在開發兩個臨床階段的藥物候選者，NXP800和NXP900。NXP800是一種口服小分子GCN2激活劑，目前正在進行一項針對鉑耐藥、ARID1a突變卵巢癌的10億期臨床試驗，並在一項研究者主導的臨床試驗中用於治療膽管癌。NXP900是一種口服小分子SRC家族激酶（SFK）抑制劑，包含SRC和YES1。NXP900具有獨特的作用機制，它能抑制SRC激酶的催化和支架功能，從而完全關閉信號通路。NXP900目前在進行Phase 1a劑量遞增研究。
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com
公司聯繫人
Ron Bentsur
董事長、首席執行官和總裁
201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
媒體關係聯繫人
克里斯托弗·M·卡拉布雷斯
LifeSci顧問
電話：917-680-5608
ccalabrese@lifesciadvisors.com
譯文內容由第三人軟體翻譯。